反应详情

Following the procedure as described in EXAMPLE 3 and making non-critical variations using 1′-(diphenylmethyl)spiro[furo[2,3-g]quinoxaline-8,3′-indol]-2′(1′H)-one to replace 1′-(diphenylmethyl)-6-methoxy-5-methylspiro[1-benzofuran-3,3′-indol]-2′(1′H)-one, spiro[furo[2,3-g]quinoxaline-8,3′-indol]-2′(1′H)-one was obtained (22%): mp 206-207° C. (ethyl acetate/hexanes); 1H NMR (300 MHz, DMSO-d6) δ10.78 (s, 1H), 8.68-8.61 (m, 2H), 8.06 (d, J=9.0 Hz, 1H), 7.68 (d, J=9.0 Hz, 1H), 7.21-7.18 (m, 1H), 7.03-6.86 (m, 3H), 6.96 (ABq, 2H); MS (ES+) m/z 289.8 (M+1).